J Clin Oncol: Patients with advanced Hodgkin's lymphoma who received full metabolic remission after ABVD chemotherapy can safely omit consolidation chemotherapy.

The HD 0607 trial (NCT00795613) is designed to study the role of consolidated radiotherapy (cRT) in advanced Hodgkin's lymphoma (cHL) that is fully metabolically relieved after chemotherapy with ammoxin, Bolemycin, chlorpyridoxine and dakabatin (ABVD) with large lymph nodes (LNM).
late stage (IIB-IVB) HL patients, the baseline is required to have LNM (maximum diameter of lymph nodes of 5 cm), and two and six POST-ABVD chemotherapy PET tests (PET-2 and PET-6) are negative.
subjects were randomly divided into two groups, subject to CRT or no further treatment (NET).
(Study Process) In 296 randomly grouped patients, 101 patients had a baseline LNM with a maximum diameter of 5-7 cm (A subgroup), 96 patients with a maximum diameter of 8-10 cm (B subgroup), and 99 patients with typical lumps (diameters of 10 cm, C subgroup).
280 (88%) patients showed RM after chemotherapy.
the median dose of cRT is 30.6 Gy (range 24-36 Gy).
5.9 years of median follow-up (non-progression survival in three subgroups with different treatment conditions (PFS) was 91% (95% CI 84%-99%) and 95% (89%) respectively in patients in subgroup A who received crRT or NET 5-100 per cent), 98 per cent (93-100 per cent) and 90 per cent (80-100 per cent) respectively in subgroup B, 89 per cent (81-98 per cent) and 86 per cent (77-96 per cent) in subgroup C.
, PET-2 and PET-6 tests were negative for HL patients who did not undergo consolidated chemotherapy and had no significant effect on survival prognostication, regardless of the size of the lymph nodes at the time of diagnosis.
.